Related Experiment Video

Updated: May 14, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Is lipid management effective for all stages of CKD?

Elaine Ku1, Vito Campese

  • 1University of California San Francisco, San Francisco, CA, USA.

Blood Purification
|January 25, 2013
PubMed

Insights

Statin therapy may not be thoroughly tested for cardiovascular risk in all chronic kidney disease (CKD) patients. This review examines statin evidence across CKD stages, including dialysis and transplant recipients.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Patients with chronic kidney disease (CKD) exhibit elevated cardiovascular morbidity and mortality.
  • Traditional cardiovascular risk factor modification, particularly dyslipidemia control, lacks comprehensive testing across all CKD stages.

Purpose of the Study:

  • To review the existing evidence for statin therapy efficacy and safety in patients with varying stages of chronic kidney disease.
  • To assess the role of statins in managing cardiovascular risk in CKD patients, including those on dialysis and kidney transplant recipients.

Main Methods:

  • Systematic review of clinical trials and observational studies.
  • Analysis of data concerning cardiovascular outcomes, mortality, and adverse events associated with statin use in CKD populations.

Main Results:

  • Evidence regarding the benefits of statins in primary prevention of cardiovascular events in CKD patients is limited.
  • Statin use in patients with advanced CKD and on dialysis has shown mixed results regarding cardiovascular risk reduction.
  • Further research is needed to clarify the role of statins in specific CKD subpopulations.

Conclusions:

  • The evidence for widespread statin use for cardiovascular risk reduction in all stages of CKD remains inconclusive.
  • Statin therapy may offer benefits in certain CKD patient groups, but careful consideration of risks and benefits is warranted.
  • More robust clinical trials are necessary to establish definitive guidelines for statin use in chronic kidney disease.

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...